These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 3918536)

  • 1. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
    Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
    Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
    Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
    Patscheke H; Stegmeier K
    Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane A2 and the endoperoxides mediate canine platelet activation.
    Harris RH; Nichols R; Schmeling JW; Ramwell PW
    Thromb Res; 1981 Sep; 23(6):521-32. PubMed ID: 6798707
    [No Abstract]   [Full Text] [Related]  

  • 5. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets.
    Hamid-Bloomfield S; Whittle BJ
    Br J Pharmacol; 1986 Aug; 88(4):931-6. PubMed ID: 3017497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D2.
    Gresele P; Deckmyn H; Huybrechts E; Vermylen J
    Biochem Pharmacol; 1984 Jul; 33(13):2083-8. PubMed ID: 6430299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
    Parry MJ
    Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arachidonic acid induces human platelet-fibrin retraction: the role of platelet cyclic endoperoxides.
    Di Minno G; Bertelé V; Cerletti C; de Gaetano G; Silver MJ
    Thromb Res; 1982 Feb; 25(4):299-306. PubMed ID: 6803385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboxane synthase inhibition causes re-direction of prostaglandin endoperoxides to prostaglandin D2 during collagen stimulated aggregation of human platelet rich plasma.
    Orchard MA; Waddell KA; Lewis PJ; Blair IA
    Thromb Res; 1985 Sep; 39(6):701-10. PubMed ID: 3936223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
    Hornberger W; Patscheke H
    Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders.
    Gresele P; Blockmans D; Deckmyn H; Vermylen J
    J Pharmacol Exp Ther; 1988 Jul; 246(1):301-7. PubMed ID: 3134542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of OKY 1581 on bronchoconstrictor responses to arachidonic acid and PGH2.
    Tilden SJ; Underwood DC; Cowen KH; Wegmann MJ; Graybar GB; Hyman AL; McNamara DB; Kadowitz PJ
    J Appl Physiol (1985); 1987 May; 62(5):2066-74. PubMed ID: 2954941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R; Nenci GG; Gresele P
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha.
    Faili A; Randon J; Vargaftig BB; Hatmi M
    Biochem Pharmacol; 1993 May; 45(9):1815-20. PubMed ID: 8388209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V; De Gaetano G
    Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
    Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
    Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
    Hornberger WB; Patscheke H
    Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thromboxane synthase inhibition potentiates washed platelet activation by endogenous and exogenous arachidonic acid.
    Patscheke H
    Biochem Pharmacol; 1985 Apr; 34(8):1151-6. PubMed ID: 3922373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.